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There is considerable interest in whether anti-oestrogens can be used to prevent breast cancer in women bearing mutations in the
BRCA1 and BRCA2 genes. The effects of oestradiol (E2), tamoxifen (TAM) and fulvestrant (FUL) on proliferation and steroid receptor
expression were assessed in normal breast epithelium taken from women at varying risks of breast cancer and implanted into athymic
nude mice, which were treated with E2 in the presence and absence of TAM or FUL. Tissue samples were taken at various time
points thereafter for assessment of proliferative activity and expression of oestrogen and progesterone receptors (ERa and PgR) by
immunohistochemistry. Oestradiol increased proliferation in the breast epithelium from women carrying mutations in the BRCA1/2
genes, those otherwise at increased risk and those at population risk of breast cancer. This increase was reduced by both TAM and
FUL in all risk groups. In the absence of E2, PgR expression was reduced in all risk groups but significantly more so in the BRCA-
mutated groups. Subsequent E2 treatment caused a rapid, complete induction of PgR expression in the population-risk group but not
in the high-risk or BRCA-mutated groups in which PgR induction was significantly delayed. These data suggest that the mechanisms by
which E2 induces breast epithelial PgR expression are impaired in BRCA1/2 mutation carriers, whereas those regulating proliferation
remain intact. We conclude that early anti-oestrogen treatment should prevent breast cancer in very high-risk women.
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Approximately 5% of all cases of breast cancer are associated with
inherited predisposition syndromes and about half of these are
attributable to mutations in the BRCA1 and BRCA2 genes (Hopper,
2001). Carriers of mutations in the BRCA1 and BRCA2 genes have
up to a 90% lifetime risk of developing breast cancer (Rebbeck,
2002) and effective preventative strategies are required for these
women.
A number of trials have now shown that endocrine agents such
as tamoxifen (TAM) or raloxifene can prevent breast cancer in
women at increased risk of the disease (Cuzick et al, 2003). The
question arises as to whether agents such as these can be used for
prevention specifically in women bearing BRCA1 or BRCA2
mutations. The prevalence of mutations in the total cohort in the
NSABP P1 trial was unknown (Fisher et al, 1998) and therefore no
conclusion regarding the effectiveness of TAM in mutation carriers
can be made from this study. It has been suggested that endocrine
agents such as TAM will not be effective in preventing breast
cancer in BRCA1 mutation carriers because the majority of
tumours (up to 80%) arising in these women are oestrogen
receptor a (ERa) negative, have a high mitotic rate and are of high
histological grade (Lakhani, 1999; Lakhani et al, 2002). All these
features are associated with resistance to endocrine therapy and it
is clear from the overview that TAM and raloxifene reduce the
incidence of ERa-positive but not -negative tumours (Cuzick et al,
2003). Against these, however, are data showing that incidence of
breast cancer in BRCA1 and BRCA2 mutation carriers is altered by
endocrine risk modifiers such as pregnancy (Rebbeck et al, 2001).
Moreover, it is becoming clear that prophylactic oophorectomy
not only reduces the incidence of ovarian cancer in mutation
carriers but also that of breast cancer (Rebbeck et al, 2002). Finally,
it has been shown that both oophorectomy and adjuvant TAM
treatment reduce the risk of contralateral breast cancer in
mutation carriers (Narod et al, 2000; Metcalfe et al, 2004). This
raises the possibility that the initial stages of tumour formation in
BRCA1 and BRCA2 mutation carriers are hormone dependent, in
which case early endocrine therapy might be an effective
prevention strategy. This possibility is not addressed by existing
trials such as the one run by the NSABP because the effects of TAM
became evident after a relatively short follow-up period, suggesting
that the anti-oestrogen was preventing progression of existing
subclinical lesions rather than inhibiting de novo tumorigenesis
(Fisher et al, 1998).
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sSignificant advances have been made towards understanding the
mechanisms by which BRCA1 and BRCA2 act. The products of
both genes are large, ubiquitously expressed proteins that have
fundamental roles in protecting and repairing the genome (Deng
and Scott, 2000; Kerr and Ashworth, 2001; Venkitaraman, 2001).
The prevailing view on the mechanism by which heterozygous
mutations in the BRCA1 and BRCA2 genes predispose to cancer is
that they provide an unstable genetic environment in which
further mutations leading to tumorigenesis are more likely to
occur (Deng and Scott, 2000). However, this does not explain why
BRCA1 or BRCA2 mutations predispose so specifically to breast
and ovarian cancer nor why BRCA1 or BRCA2 insufficiency can
have profound effects on processes such as proliferation and
differentiation. For example, global deletion of either gene in mice
leads to embryonic lethality due to defects in proliferation and/or
differentiation as well as genetic instability (Deng and Scott, 2000;
Deng and Brodie, 2001). Conditional mutation of BRCA1 in the
mammary epithelium results in abnormal gland formation and
increased apoptosis (Xu et al, 1999; Brown et al, 2002). Both
BRCA1 and BRCA2 are expressed in tissues undergoing rapid
proliferation prior to undergoing terminal differentiation includ-
ing the pregnant mammary gland (Chodosh, 1998). In addition, in
vitro studies indicate that BRCA1, in particular, interacts with and
represses both nuclear and nongenomic ERa signalling pathways
(Fan et al, 1999; Fan et al, 2001; Razandi et al, 2004). These data
raise the possibility that proliferation and expression of oestrogen-
regulated genes are altered in oestrogen target tissues such as the
mammary gland. The aims of the present study were two-fold:
first, to determine whether BRCA1 or BRCA2 haploinsufficiency
altered the oestrogen sensitivity of normal breast epithelium in
terms of proliferation and induction of oestrogen-induced genes.
The second aim was to find out whether tamoxifen, a selective
oestrogen receptor modulator (SERM) and fulvestrant, an anti-
oestrogen devoid of agonist activity, were able to abrogate the
proliferative effects of E2 on normal breast tissue from women
carrying BRCA1 and BRCA2 mutations or who were, otherwise, at
increased risk of developing breast cancer. To do this, we used a
model of normal human breast tissue implanted into athymic nude
mice where it was treated with oestradiol (E2) and/or anti-
oestrogens. We show that epithelial proliferation in breast tissue
from women with BRCA1 and BRCA2 mutations or who are
otherwise at high risk is stimulated by oestradiol to the same
extent to that in tissue taken from women at population risk of
breast cancer. The effects of E2 on proliferation could be reduced
by the addition of TAM or fulvestrant in all three risk groups.
However, induction of progesterone receptor expression by E2 was
impaired in the tissue taken from BRCA1 and BRCA2 carriers
compared to that taken from women at population risk of breast
cancer.
MATERIALS AND METHODS
Subjects
Breast tissue was obtained from women at the population risk of
breast cancer (n¼22) at surgery for removal of a fibroadenoma as
described previously (Laidlaw et al, 1995). ‘Mutated’ tissue was
obtained at prophylactic mastectomy from women with documen-
ted linkage to or mutations in the BRCA1 (n¼5) or BRCA2 genes
(n¼3). In the case of BRCA1, one subject was shown to be a
mutation carrier through linkage analysis, but was not sequenced,
whereas the other four were characterised by direct sequencing
which identified the following mutations: 185delAG, 1294del40,
502del5 and 2799delAA. The three subjects with BRCA2 mutations
were related and direct sequencing confirmed that they had the
same lesion, 6819delTG. ‘Increased-risk’ tissue was taken at either
prophylactic mastectomy or biopsy in women judged to be at
increased risk of breast cancer either by family history or a
previous history of cancer (n¼18). Of these, 12 were undergoing
bilateral prophylactic mastectomy because their family history
indicated a lifetime risk of breast cancer greater than one in four,
three were undergoing prophylactic removal of an uninvolved
breast contralateral to one containing tumour and in three cases,
tissue was obtained at biopsy from women with a more moderate
family history calculated to put them at a lifetime risk of one in six
or greater. The three groups (population risk, mutation carriers
and high risk) of women were well matched for age at operation
and for endocrine breast cancer risk factors such as age at
menarche, parity and age at first full-term pregnancy (see Table 1).
The study was approved by the Ethics Committee of the South
Manchester Hospitals and all subjects gave informed consent for
the use of their normal tissue in research studies. In all cases, the
Table 1 Characteristics of the subjects from whom tissue was taken for
analysis of the effects of oestradiol and anti-oestrogens on proliferation and
steroid receptor expression in normal breast epithelium
Population
risk Mutated
High
risk
Age at operation (years)
All subjects
Median 36.5 37 37.5 nsd
a
Range 16–46 29–53 24–54
n 22 8 18
Subjects whose tissue was implanted
Median 40 39 38.5 nsd
Range 31.5–44 29–53 25–54
n 97 1 2
Age at menarche (years)
All subjects
Median 13 13 12.5 nsd
Range 10.5–16 11–15 10–16
n 20 7 18
Subjects whose tissue was implanted
Median 12.25 13 12.5 nsd
Range 11.5–16 11–15 11–15
n 96 1 2
Parity
All subjects
Median 2 2 2
Range 0–4 0–3 0–7 nsd
n 22 8 18
Subjects whose tissue was implanted
Median 2 2 3 nsd
Range 0–4 0–3 0–7
n 97 1 2
Age at FFTP
b (years)
All subjects
Median 22 25.5 21
Range 17–33 19–35 17–30 nsd
n 17 6 15
Subjects whose tissue was implanted
Median 21.5 25.5 21 nsd
Range 18–33 19–35 19–30
n 86 1 1
Population risk¼women at population risk of breast cancer undergoing removal of a
fibroadenoma; ‘Mutated’¼women carrying mutations in the BRCA1 and BRCA2
genes undergoing prophylactic mastectomy; High risk¼women at very high risk of
breast cancer due to family history also undergoing prophylactic mastectomy or
biopsy in women judged to be at increased risk of breast cancer either by family
history or a previous history of cancer.
ansd¼no significant difference between the
risk groups by Kruskal–Wallis test.
bFFTP¼first full-term pregnancy.
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stissue used in the implantation studies was examined by an
experienced histopathologist (Dr J Coyne) to confirm the presence
of normal lobules only. Tissue samples from nine of the 22
population-risk subjects, seven of the eight samples of the
‘mutated’ tissue and 12 of the 18 ‘increased-risk’ samples were
used for the implantation studies.
Implantation of breast tissue into athymic nude mice
All the following procedures were carried out under the Animals
(Scientific Procedures) Act of 1986 and complied with UKCCCR
Guidelines regarding the ethical use of animals. Implantation of
human breast tissue into athymic nude mice was performed as
described previously (Laidlaw et al, 1995). Each sample of breast
tissue was divided into small pieces (2 2 1mm), eight of which
were implanted subcutaneously (s.c.) into each of at least 16 intact
female adult (9–10 weeks old) nu/nu, balb/c mice. At 2 weeks after
tissue implantation, control silastic pellets were inserted s.c. into
four of the mice, whereas two groups of six mice received 0.5 or
2.0mg E2-silastic pellets prepared as described previously (Laidlaw
et al, 1995). After 1 week, the two groups of E2-treated mice were
subdivided such that two mice received injections of the partial
agonist anti-oestrogen TAM (1mg mouse
 1 day
 1 in peanut oil
s.c.), two received the specific anti-oestrogen fulvestrant (ICI 182
780; 5mg mouse
 1 week
 1 s.c. in castor oil) and two the
appropriate vehicle control (peanut or castor oil). These doses
were chosen because they had been shown to inhibit the growth of
MCF-7 human breast tumours in athymic nude mice (Osborne
et al, 1995) and treatments were continued for 2 weeks. Two tissue
samples were removed from each of the mice 2, 3, 4 and 5 weeks
after implantation, fixed in 4% buffered formalin overnight at 41C,
then embedded in paraffin wax. Blood was taken from the mice at
the conclusion of each experiment and serum E2 levels were
assayed by RIA as described (Laidlaw et al, 1995). The median
serum E2 concentration in the mice treated with control silastic
pellets was 107pM with an interquartile (IQ) range of 74–214pM
(n¼100), those treated with 0.5mg E2 pellets had a final median
concentration of 386pM (IQ range 268–745pM; n¼59), whereas
those treated with 2mg E2 pellets achieved a final median serum
concentration of 1050pM (IQ range 785–1660pM; n¼57).
Immunohistochemical assessment of proliferation and
steroid receptor expression
Proliferative activity was assessed by immunohistochemistry (IHC)
using the mouse monoclonal antibody MIB-1 (Coulter Ltd, UK)
raised against the Ki67 proliferation-associated antigen. Expres-
sion of ERa and PgR was determined by IHC using a mouse
monoclonal anti-ERa antibody (clone ID5, Dako Ltd, UK) and a rat
monoclonal anti-PR antibody (clone KD68, Abbott Laboratories,
UK), respectively. Microwave antigen retrieval methods and
dilutions were as described previously (Clarke et al, 1997a).
Antibody binding was detected indirectly using the appropriate
biotinylated second antibodies, a peroxidase-conjugated avidin–
biotin complex (ABC Elite, Vector Laboratories, UK) and
diaminobenzidine as the chromogen. Quantitation of immuno-
staining was carried out on a light microscope and was restricted
to the epithelial cells of the terminal duct lobulo-alveolar units.
Areas to be counted were selected out of focus at low power and
then complete high-power fields were scored. At least 1000
epithelial cells were scored per sample and the number of labelled
cells was expressed as a percentage of the total cells counted. The
intensity of staining was not assessed.
Statistical methods
Throughout, the data are presented as medians together with their
respective interquartile ranges (IQRs). Overall changes across
treatment or risk groups were analysed using the Kruskal–Wallis
nonparametric, one-way analysis of variance. If this proved
significant at the 5% level, then pairwise comparisons were made
using the nonparametric Mann–Whitney U-test.
RESULTS
Oestradiol stimulates breast epithelial cell proliferative
activity in all risk groups
Analysis of the tissue samples, fixed at the time of removal
from the patients, revealed no differences in the percentages of
breast epithelial cells labelled with the anti-Ki67 antibody between
the different risk groups (see Table 2). At 2 weeks after
implantation into the mice and before treatment commenced,
epithelial Ki67 expression decreased to approximately 1%
and, again, there were no significant differences between the
samples taken from the different risk groups (see Table 3 and
Figure 1). Figure 1 shows the proliferative activity of the tissue
samples from the different risk groups taken before (day 0)
and 1 week (day 7) after the start of E2 or control treatment. In
the absence of E2, epithelial Ki67 expression in the tissue samples
from the population- and high-risk tissue groups remained
at the levels seen before treatment (Figure 1A and B). The median
Ki67LI in the tissue samples from the ‘All mutations’
group (Figure 1C) decreased although not significantly so.
However, separate analysis of the samples from women bearing
BRCA1 mutations (Figure 1D) indicated that, in the absence
of E2, the epithelial Ki67LI decreased significantly to a median of
0.7% (IQR¼0.4–1.0; n¼21; P¼0.009 by Mann–Whitney U-test).
The reasons for this decline in proliferative activity in the
tissue taken from women carrying BRCA1 mutations compared
to that from women at population risk are not clear at present,
but it may be due simply to the variability in the data from the
latter group. Figure 1 also shows the breast epithelial Ki67LIs
in each of the risk groups after 1 week’s treatment with 0.5 and
2mg E 2. In the population-risk group, there was an increase
in the Ki67LI after treatment with the 0.5mg E2 pellet although
this was not statistically significant. In the other three risk
groups, the Ki67LI increased significantly after treatment with
the low-dose E2 pellet (Po0.001 by Mann–Whitney U-test)
Table 2 Proliferation (Ki67), oestrogen receptor alpha (ERa) and
progesterone receptor (PgR) expression in samples of breast epithelium
taken from women at population risk of breast cancer undergoing removal
of a fibroadenoma, from BRCA1 or BRCA2 mutation carriers undergoing
prophylactic mastectomy (‘mutated’) or from women at high risk of breast
cancer also undergoing prophylactic mastectomy or biopsy in women
judged to be at increased risk of breast cancer either by family history or a
previous history of cancer
Population
risk
High
risk BRCA1+BRCA2
BRCA1
only
n 22 18 8 5
Ki67 (%)
Median 2.3 1.5 2.9 2.9 nsd
b
IQ range
a 1.3–8.2 1.1–3.5 0.9–4.0 0.7–4.8
ERa (%)
Median 27.9 21.6 29.6 27.3 nsd
IQ range 16.9–32.9 17.3–35.8 12.2–35.2 13.2–36.0
PgR (%)
Median 24.8 20.6 19.5 15.3 nsd
IQ range 16.3–35.6 15.9–26.4 9.4–28.8 4.8–24.7
The figures represent the proportion of positively stained epithelial cells expressed as
a percentage of the total number of cells counted.
aIQ range – interquartile range.
bnsd¼no significant difference between the three risk groups by Kruskal–Wallis test.
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scompared to the appropriate untreated control. Treatment with
the high-dose (2mg) E2 pellet (Figure 1C) significantly increased
the median Ki67LIs in all four of the risk groups (Po0.001 by
Mann–Whitney U-test) when compared to the corresponding
control values.
Induction of progesterone receptor expression by
oestradiol is impaired in breast tissue from BRCA
mutation carriers
There were no significant differences in the levels of breast
epithelial cell ERa and PgR expression between the risk groups at
the time tissue was removed from the women (Table 2). However,
14 days after implantation into untreated mice, there was a
significant decrease in the percentage of PgR-positive cells in all
risk groups (Table 3). This was most pronounced in the tissue
samples from women bearing BRCA1 mutations and resulted in
the percentage of PgR-positive cells being approximately four-fold
lower than that of the population-risk group (Po0.001 by Mann–
Whitney U-test). Figure 2 shows the effects of 1 week’s treatment
with control, low- and high-dose E2-silastic pellets on PgR
expression in breast epithelial cells. Levels of PgR expression were
not altered in the control-treated samples (Figure 2A), and the
differences between the risk groups were maintained. Figure 2B
shows that treatment with the low-dose E2 pellet increased
epithelial cell PgR expression in samples from all the risk groups.
However, the responses to low-dose E2 in the All mutations and
BRCA1 groups were attenuated such that the percentages of PgR-
positive epithelial cells were increased only to 9.6% (IQR¼4.9–
21.3) and 6.8% (IQR¼2.1–20.4), respectively. These increases in
PgR expression in the samples from the All mutations and BRCA1
groups almost, but not quite, reached statistical significance when
compared to the corresponding control-treated samples (P¼0.051
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Figure 1 Proliferative activity of normal breast epithelium taken from women at population risk of breast cancer (A), those at high risk (B) All BRCA1
or BRCA2 mutation carriers (C) and BRCA1 mutation carriers only (D), which had been implanted into athymic nude mice before (day 0) and after 1 week’s
treatment with control, 0.5mg E2 or 2.0mg E2-silastic pellets. The thick horizontal lines indicate the median values as do the figures above the columns
indicating the IQRs. The numbers in parentheses are the numbers of samples available for analysis in each group and the P-values indicate the significance of
the differences across the treatment groups by Kruskal–Wallis nonparametric analysis of variance. Ctrl¼control.
Table 3 Proliferation (Ki67) and progesterone receptor (PgR) expres-
sion in samples of human breast epithelium 14 days after being implanted
into the athymic nude mice and before the initiation of treatment
Population
risk
High
risk BRCA1 + BRCA2
BRCA1
only
Ki67 (%)
Median 1.08 1.16 1.21 1.25 nsd
a
IQ range
b 0.3–2.45 0.50–2.30 0.57–3.28 0.61–2.84
n
c 110 169 102 66
PgR (%)
Median 9.60 9.12 2.94 1.99 Po0.001
a
IQ range 5.34–18.48 4.32–15.30 0.96–8.51 0.90–5.04
n 63 101 86 52
The figures represent positively stained epithelial cells expressed as a percentage of
the total number of cells counted.
aSignificance of comparison between risk groups by
Kruskal–Wallis test; nsd¼no significant difference.
bIQ range¼inter-quartile range.
cn¼number of tissue samples in which parameter could be measured.
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sand 0.07, respectively, by Mann–Whitney U-test). Expression of
the PgR in breast epithelium from all the risk groups was also
induced by 1 week’s treatment with high-dose E2 (Figure 2C).
However, the increase in the samples from the high-risk group did
not reach the same level as that in the population-risk samples
(P¼0.002 by Mann–Whitney U-test). The responses in the All
Mutations and BRCA1 groups were diminished considerably in
that they reached medians of only 10.3% (IQR¼4.6–19.2) and
9.3% (IQR¼4.4–20.0), respectively (P¼0.062 and 0.012 vs
corresponding control-treated samples by Mann–Whitney U-test).
The effects of the high-dose E2 pellet on PgR expression in
human breast epithelium at all time points after the start of
treatment are shown in Figure 3. In the tissue samples from the
population-risk group, PgR expression was maximal after 1 week
of treatment with the high-dose E2 pellet and this level was
maintained for the remainder of the experimental period. In
contrast, the response in the All mutations group was attenuated
such that percentages of PgR-positive cells in samples from this
group were significantly lower than those of the population-risk
group not only before the start of treatment but also for 2 weeks
afterwards (Po0.001 by Mann–Whitney U-test at each time
point). By the final time point, the median percentage of PgR-
positive cells in samples from the All Mutations group had
increased such that it approximated to that of the population-risk
group. The effects of E2 on PgR expression in tissue samples from
the BRCA1 group could not be examined separately due to the
small number of tissue samples available for analysis at the later
time points. Examination of the effects of E2 on PgR expression in
the tissue samples from the high-risk group of women confirmed
the results shown above in that the percentage of PgR-positive
epithelial cells in this group after 1 week of high-dose E2 treatment
was significantly lower than that of the population-risk group but
thereafter, there were no significant differences between the two
groups.
Tamoxifen and fulvestrant reverse the effects of E2 on
breast epithelial cell proliferative activity in all risk groups
Figure 4 shows Ki67 expression in normal breast tissue samples
taken from the mice after treatment with 0.5mg E2 for 1 week
followed by a further 2 weeks of treatment in which the E2 was
combined with either TAM or fulvestrant. An additional group of
mice were treated with 0.5mg E2 only, whereas the negative control
group received vehicle alone. Treatment with 0.5mg E2 was
sufficient to increase Ki67 expression in the population-risk, high-
risk and All mutations groups (Figures 4A, B and C; Po0.01 by
Mann–Whitney U-test compared to the appropriate untreated
control for each risk group). Addition of TAM at a dose of 1mg
mouse
 1 day
 1 reduced expression of Ki67 in these three risk
groups compared to 0.5mg E2 alone (Po0.05 by Mann–Whitney
U-test in each risk group). The percentage of Ki67-positive cells
was also reduced by the addition of fulvestrant (5mg mouse
 1
week
 1) in the population risk, increased¼risk and All Mutations
groups compared to 0.5mg E2 alone (Figure 4A, B and C; Po0.05
by Mann–Whitney U-test in each risk group). Both TAM and
fulvestrant, when added to 0.5mg E2, reduced the median
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Figure 2 Progesterone receptor expression in normal breast epithelium taken from women at population risk of breast cancer, those at high risk and
those carrying BRCA1 and BRCA2 mutations, which had been implanted into athymic nude mice and treated for 1 week with control, (A), 0.5mg E2 (B)o r
2.0mg E2 (C)-silastic pellets. The thick horizontal lines indicate the median values as do the figures above the columns indicating the IQRs. The numbers in
parentheses are the numbers of samples available for analysis in each group and the P-values indicate the significance of the differences across the risk groups
by Kruskal–Wallis nonparametric analysis of variance. PgR¼progesterone receptor; PR¼population risk; HR¼high risk; All muts¼all mutations; BRCA1
only¼BRCA1 mutation carriers only.
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Figure 3 The effects of E2 treatment over time on progesterone
receptor expression in breast epithelium from women at population risk of
breast cancer (E) compared to that from women at high risk (’) and
those carrying BRCA1 and BRCA2 mutations (m). The median values are
represented by the solid symbols, whereas the error bars indicate the IQRs
and the numbers in parentheses are the samples available for analysis in
each group. *Po0.05, **Po0.01 and ***Po0.001 compared to the
population risk group by Mann–Whitney U-test. PgR¼progesterone
receptor.
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spercentages of Ki67-positive breast epithelial cells to the levels seen
in untreated controls in the population-risk, increased-risk and all
mutations groups (no significant difference when compared to
controls by Mann–Whitney U-test in each risk group). Separate
analysis of the tissue samples from women bearing BRCA1
mutations (Figure 4D) showed that the effects of 0.5mg E2 in the
absence and presence of TAM or fulvestrant did not quite reach
statistical significance (P¼0.084 by Kruskal–Wallis test) although
the pattern of changes reflected those seen in the other risk groups.
The ability of TAM and fulvestrant to reverse the effects of high-
dose (2mg) E2 treatment on breast epithelial cell Ki67 expression
was also investigated (data not shown). Both anti-oestrogens could
reduce the effects of E2 on proliferation in all the risk groups but
their effects were rather more variable presumably because the
serum drug levels achieved with the above dosing schedules were
not sufficient to overcome the high plasma E2 levels reached after
treatment with the 2mg E2 pellet.
DISCUSSION
The effects of heterozygous mutations in the BRCA1 or BRCA2
breast cancer-predisposing genes on the endocrine sensitivity of
human breast epithelial cells are unknown. It is important to
determine what these effects may be because of the increasing use
of endocrine agents such as TAM for breast cancer prevention in
BRCA1 and BRCA2 mutation carriers. Although the BRCA1 and
BRCA2 proteins play critical roles in DNA damage repair (Brodie
and Deng, 2001; Deng and Brodie, 2001; Kerr and Ashworth, 2001),
in vitro studies suggest that the BRCA1 gene product can also
interact with and suppress the activity of the ERa (Fan et al, 1999;
Fan et al, 2001). As E2 is the major steroid mitogen for the human
breast epithelium acting via the ERa, it might be predicted that
BRCA1 and, possibly, BRCA2 haploinsufficiency would result in an
enhanced proliferative response to E2. The present data show that
this is not the case as proliferation of breast epithelium from
mutation carriers in response to E2 treatment does not differ
significantly from that of tissue from women at population risk of
the disease. Secondly, it might be predicted that BRCA1 and
BRCA2 haploinsufficiency would confer anti-oestrogen resistance
to the breast epithelium. Again, we show that this is not the case as
both the SERM TAM and the specific anti-oestrogen fulvestrant
could reverse the effects of E2 on proliferation. Both anti-
oestrogens also reversed the proliferative effects of E2 in tissue
from women at high risk of breast cancer because of their family
history. These findings lead us to suggest that early intervention to
antagonise the effects of E2 or reduce serum E2 levels would be
effective for the prevention of breast cancer in BRCA1 or BRCA2
mutation carriers. As both the BRCA1 and BRCA2 proteins are
involved in postreplicative DNA repair (Brodie and Deng, 2001;
Deng and Brodie, 2001; Kerr and Ashworth, 2001), reducing the
proliferative activity of the breast luminal epithelial cell population
from which most tumours are derived should reduce the number
of opportunities for replication errors to occur. The propagation of
potentially transforming mutations might also be reduced.
Although there are no apparent alterations in the proliferative
activity of the tissue from BRCA1 and BRCA2 mutation carriers, we
have been able to detect a defect in the kinetics of PgR induction
by E2. As far as we are aware, this is one of the first reports of a
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Figure 4 The proliferative activity of normal breast epithelium taken from women at population risk of breast cancer (A), those at high risk (B), those
carrying BRCA1 and BRCA2 mutations (C) and BRCA1 mutation carriers only (D) after implantation into athymic nude mice and treatment with 0.5mg E2 for
1 week followed by 2 weeks of E2 combined with either TAM or fulvestrant. The thick horizontal lines indicate the medians as do the numbers on top of the
columns indicating the IQRs. The numbers in parentheses are the numbers of samples available for analysis in each treatment group and the P-values indicate
the significance of the differences across the treatment groups by the Kruskal–Wallis nonparametric analysis of variance. Ctrl¼control; 0.5mg
E2¼treatment with 0.5mg E2-silastic pellets; TAM¼tamoxifen (1mg mouse
 1 day
 1); FUL¼fulvestrant (5mg mouse
 1 week
 1).
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sbiological phenotype associated with heterozygous mutations in
the BRCA1 and BRCA2 genes, and complements the recent reports
of an effect on PgR expression by Mote et al (2004). The delayed
PgR response to E2 in the mutation carriers is paradoxical in the
face of the in vitro evidence suggesting that the BRCA1 gene
product is a repressor of both nuclear and nongenomic mechan-
isms of ERa action (Fan et al, 1999, 2001; Razandi et al, 2004).
However, some of these experiments used reporter constructs
containing a consensus oestrogen response element (ERE) from
the vitellogenin gene to examine the effects of the BRCA1 protein
on ERa transcriptional activity (Fan et al, 1999), whereas others
have shown that overexpression of BRCA1 abrogates the effects of
E2 on expression of the oestrogen-induced genes, pS2 and
cathepsin D (Fan et al, 2001). The PgR gene promoter does not
contain a complete ERE but it does have ERE half sites adjacent to
those for Sp-1 (Petz and Nardulli, 2000), and it is possible that the
BRCA1 protein has significantly different effects at this site in
human breast epithelium in vivo. Alternatively, the differences in
expression of PgR in response to E2 treatment may result from an
alteration in the ratio of the A and B isoforms of the PR. Many
commercially available antibodies used for PgR IHC fail to detect
the B form of the receptor in formalin-fixed, paraffin-embedded
tissues (Mote et al, 2001). The specificity of the antibody used in
the present study is not known at present, but it is probable that it
also does not detect PgRB in routinely processed tissue. Therefore,
the apparent alteration in PgR induction following E2 treatment of
tissue from women with BRCA mutations may reflect an alteration
in the PgRA to PgRB ratio such that PgRB expression is increased
at the expense of PgRA. One way of confirming this would be to
use more specific antibodies to determine the ratios of the two PgR
isoforms in the breast epithelium from the mutation carriers
compared to those from subjects at population risk of breast
cancer. This approach has been used by Mote et al (2004) who
have shown that not only is the ratio of PgRA to PgRB altered in
favour of PgRA in normal breast tissue taken from BRCA1 and
BRCA2 mutation carriers but also that expression of both isoforms
is markedly reduced compared to tissue from normal-risk women.
This suggests that the reduced levels of PgR expression seen in the
mutation carriers in the present study is due to a reduction in both
PgR isoforms. Finally, we have shown that luminal epithelial cells
that proliferate in response to E2 do not contain the ERa, whereas
PgR is expressed only in ERa-positive cells (Clarke et al, 1997b).
Clearly, BRCA1 would act as a coregulator of ERa activity only in
cells that contain the receptor; therefore, we might expect BRCA1
to be involved directly in the control of PgR expression but not
proliferation and this is supported by the present data. It will be
important to determine exactly how the BRCA1 and BRCA2 gene
products contribute to the control of PgR expression in the human
breast epithelium. The effects of E2 on PgR expression in tissue
from the high-risk group of women also appeared to be altered
although the differences between this group and the population
risk group just failed to reach significance. This may reflect the fact
that many of the women in this risk group were given a probability
of developing breast cancer of at least one in four based on their
family history. Accordingly, one in four of these women could be
carrying BRCA1 and BRCA2 mutations, whereas the others will be
at population risk of the disease. This would dilute the alteration in
the effects of E2 on PgR expression associated with BRCA gene
mutations in this group.
A potential criticism of our line of thinking could be that there is
no haploinsufficient effect of a BRCA1 or BRCA2 mutation, and that
anti-oestrogen treatment functions only as a secondary preventer of
breast cancer. Given that primary prevention of breast cancer
would have to take place at least 6 and possibly 10 years prior to a
clinically apparent breast tumour being detected, none of the
prevention trials and particularly not the NSABP trial (King et al,
2001) would have been powered to detect a primary preventive role.
There is nonetheless evidence from BRCA1 mutation carriers that
TAM may be effective in long-term prevention of second primary
cancers and part of this is likely to be due to a primary preventive
role. This is because the level of reduction seen would not be
consistent with secondary prevention of what are mostly ER-
negative tumours (Narod et al, 2000; Metcalfe et al, 2004). That
primary prevention of breast cancer in BRCA carriers occurs by
reducing oestrogen stimulation of the breast is now beyond dispute.
Oophorectomy prior to the menopause substantially reduces the
risks of breast cancer (Rebbeck et al, 2001, 2002). Even though
BRCA1 cancers are thought to derive from basal cells that are ER
negative, these cells are still under the influence of neighbouring
ER-positive epithelial cells. Reducing the growth-inducing signals
of these cells will potentially reduce proliferation of the basal cells
and reduce the chances of introducing mutations during cell
division by naturally occurring replication error. Even if there is no
heterozygous effect on the cell of carrying a BRCA mutation, anti-
oestrogen treatment is still likely to be effective in primary
prevention by this mechanism. Yet, there may well be a
haploinsufficient effect. We have shown that there does appear to
be a difference between BRCA1-mutated epithelial cells and
controls. Moreover, Kote-Jarai et al (2004) have shown that
fibroblasts from BRCA1 mutation carriers can be distinguished
from controls in terms of their response to radiation damage in
microarray analysis. The elusive haploinsufficient effect and a
functional assay for the heterozygous state may not be too far away.
In summary, we have shown that E2-stimulated proliferation in
breast epithelium taken from women bearing heterozygous
mutations in the BRCA1 and BRCA2 genes can be reversed by
both a SERM (TAM) and an anti-oestrogen (fulvestrant) that is
without agonist effects. We have also shown that altered
expression of PgR is a phenotype associated with mutations in
the BRCA1 and BRCA2 genes. We conclude that early anti-
oestrogen treatment should be effective for the prevention of
breast cancer in high-risk women.
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